| 书目名称 | Immunotherapy |
| 编辑 | Aung Naing,Joud Hajjar |
| 视频video | http://file.papertrans.cn/463/462296/462296.mp4 |
| 概述 | Highlights the significant developments in the field of immuno-oncology to inform the scientific community.Summarizes diverse immunotherapeutic approaches for management of cancer to update profession |
| 丛书名称 | Advances in Experimental Medicine and Biology |
| 图书封面 |  |
| 描述 | .The second edition of .Immunotherapy .is an updated overview of immuno-oncology in acute myleloid leukemia, non-small cell lung cancer and melanoma, showcasing advances in the management of cancer broadly classified as hematological malignancies and solid tumors. Though the spectrum of clinical activity and duration of response seen with these agents is promising, objective response is limited to a subset of patients and is often associated with distinct side effects that are potentially life-threatening. With increasing use of checkpoint inhibitors as standard of care and in clinical trials, the burden of immune-related adverse events will undoubtedly increase. Given these limitations and increase in health care costs associated with such therapies, it is essential to identify patients who are likely to respond to immunotherapy and those who are at a risk for developing treatment-related side effects. ..This new edition will inform readers on the latest in biomarker development to identify patients who are more likely to respond, and strategies to overcome the challenges of immune-related adverse events. In addition, the authors recognize that including the missing patient voice |
| 出版日期 | Book 20182nd edition |
| 关键词 | Immunotherapy; Translational cancer immunology; Vaccine; IL-10; ImmunoOncology |
| 版次 | 2 |
| doi | https://doi.org/10.1007/978-3-030-02505-2 |
| isbn_softcover | 978-3-030-37856-1 |
| isbn_ebook | 978-3-030-02505-2Series ISSN 0065-2598 Series E-ISSN 2214-8019 |
| issn_series | 0065-2598 |
| copyright | Springer Nature Switzerland AG 2018 |
|Archiver|手机版|小黑屋|
派博传思国际
( 京公网安备110108008328)
GMT+8, 2025-8-18 22:59
发表于 2025-3-21 19:32:59
